Biomolecular predictors of urothelial cancer behavior and treatment outcomes

Michael Rink, Eugene K. Cha, David Green, Jens Hansen, Brian D. Robinson, Yair Lotan, Arthur I Sagalowsky, Felix X. Chun, Pierre I. Karakiewicz, Margit Fisch, Douglas S. Scherr, Shahrokh F. Shariat

Research output: Contribution to journalReview article

47 Scopus citations

Abstract

Urothelial carcinoma of the urinary bladder (UCB) is a highly heterogeneous malignancy that causes significant morbidity and mortality. Despite advances in surgical and medical treatment, there has been no change in mortality in UCB over the past decades. Standard pathological features (stage, grade, nodal status) provide only limited information regarding biological potential and clinical behavior. Molecular biomarkers may shed light on important mechanisms of pathogenesis, provide useful additional prognostic information, and serve as targets for therapy. This review summarizes recent advances and the most promising UCB tissue and blood biomarkers of the past few years. We discuss the predictive and prognostic value of biomarkers at different stages of UCB. There is no doubt that a panel of biomarkers will eventually improve our clinical decision-making with regard to treatment and follow-up.

Original languageEnglish (US)
Pages (from-to)122-135
Number of pages14
JournalCurrent urology reports
Volume13
Issue number2
DOIs
StatePublished - Apr 1 2012

    Fingerprint

Keywords

  • Biomarker
  • Bladder cancer
  • Molecular marker
  • Prediction
  • Prognosis
  • Survival
  • Urothelial carcinoma

ASJC Scopus subject areas

  • Urology

Cite this

Rink, M., Cha, E. K., Green, D., Hansen, J., Robinson, B. D., Lotan, Y., Sagalowsky, A. I., Chun, F. X., Karakiewicz, P. I., Fisch, M., Scherr, D. S., & Shariat, S. F. (2012). Biomolecular predictors of urothelial cancer behavior and treatment outcomes. Current urology reports, 13(2), 122-135. https://doi.org/10.1007/s11934-012-0237-1